You are currently viewing Gyntools Begins Pilot Program for Vaginitis Screening for Women of IDF

Gyntools is about to undertake a pilot study with the Israel Defense Force (IDF) in order to screen for Vaginitis in women who are serving in the IDF. Military service is mandatory and it can take incredibly long periods of time until a female soldier is able to see a military gynecologist for an examination. Gyntools will step in and diagnose women at their home army base within minutes. Based on the results of the testing, a physician is able to prescribe the proper medication in order to provide proper and timely treatment.

Vaginitis is the most common gynecological condition with 3 out of 4 women suffering from it at least once in their lifetime. It is the most common cause of clinical visits each year. Unfortunately, although the high prevalence, Vaginitis is misdiagnosed today in 50% of first clinical visits. This causes an increased financial burden to payers totaling more than $3 billion in redundant expenses yearly.

Gyntools aimed to change the standard of care and provide accuracy to their patients. They’ve developed an incredible artificial intelligence diagnostic system for use in gynecology clinics and pharmacies that’s able to provide rapid diagnostic solutions through vaginal discharge collection. They’ve also developed an at-home self-test kit that can diagnose non-infectious and infectious conditions of vaginitis. This diagnostic device called Gyni is portable, proven to be 90% accurate, and takes only a few minutes.

“Gyni would be an ideal tool in our practices, replacing normal microscopy in conditions where it would not be ideal. Furthermore, it would definitely contribute to money and time saving management, helping to make our medical service more adequate and affordable at the same time. Finally it enables follow up of treated patients to confrim return to normal microflora states”, stated Professor Gilbert Donders; Belgium Director Femicare. “Finally, gynecologists can accurately diagnose vaginitis within five minutes!”

The Gyni devices work using automated microscopy, pH measurements and the consideration of patient symptoms in an automated diagnostic process carried out through deep learning. Gyni provides six different diagnoses, including mixed conditions, just by taking a single vaginal swab.

The test results were so positive that gynecologists and specialists in Israel have joined Gyntools’ seed investment round. The study also sparked interest from European specialists when presented in November at the 2018 III ISIDOG Congress. The study collected 5 000 microscopy images from 300 patients, which were classified by a specialist. A total of 85 % of them were used to train Gyni’s software model; the rest were used for testing. In one case, the developers noticed the Gyni device’s diagnosis did not match the experts’ one. However, when the expert reviewed the images taken by the Gyni device, she agreed its mixed infection diagnosis was better than her single condition diagnosis.

Gyntools started commercializing in Switzerland and Israeli HMO, where the commercial pilot is. Gyntools hopes to establish itself in the American and European markets by 2023. Gyntools is an alumnus of the Swiss accelerator Tech4eva and of the Hadassah Accelerator powered by IBM Alpha Zone.

Gyntools is currently looking for $10 million through A financing round. The technology has the potential to generate over $9B / year. The technology can be sold in walk-in clinics, pharmacy chains, women’s health centers.

“I envy the investors for the good idea and recommend the Gyni diagnostic system for cervicovaginal discharge”, stated Professor Werner Mendling; German Center for Gynecological Infections and Founder and Director, Helios Kliniken GmbH.

About Gyntools

Gyntools was founded in 2016 and is led by a fantastic team that includes Prof’ Ahinoam Lev Sagie, MD, senior OB-GYN (CMO), Nimrod Lev (CEO), and Meny Lev Sagie (CTO). Prof. Ahinoam Lev-Sagie, a senior OB-GYN recognized the high demand for her service. With a passion to help the women suffering she turned to her brother (Nimrod) and husband (Meny) to help the situation. The first two years of the company were devoted to exploring the data and research of the market. By 2018 the company received its first seed investment which was followed by receiving an IAI grant in order to fully develop the technology.

Gyntools is developing an FDA/CE approved, deep-learning, AI-based diagnostic tool for health. Their automated, patient-centric solution is designed to diagnose various causes of vaginal inflammation presenting with discharge, itching, or pain.

For further information contact

Nimrod Lev: 

nimrod AT gyntools.com

Learn more: https://youtu.be/MvL9aGm6B7A

https://www.gyntools.com/

About JLM- BioCity

News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/. Join the JLM-BioCity LinkedIn group at https://www.linkedin.com/groups/7060787 https://www.linkedin.com/groups/7060787 to get the news updates sent to you and to be part of the JLM-BioCity community.

JLM- BioCity is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.

We invite you, researcher, professional, investor, and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.

If you want your company featured in our blogs, news releases, please contact: info AT jlm-biocity.org

 

Source: Tech4Ev https://www.tech4eva.ch/post/the-revolution-for-diagnostics